Back to resultsOnline Yoga and the Impact on Psychosis
Primary Purpose
Psychosis
Status
Unknown status
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Yoga
Mindfulness
Sponsored by
About this trial
This is an interventional treatment trial for Psychosis focused on measuring Psychosis, Yoga, Mindfulness, Recovery, Online
Eligibility Criteria
Inclusion Criteria:
For clinical participants:
- primary diagnosis of a schizophrenia-spectrum disorder (schizophrenia, schizophreniform, schizoaffective) or related psychotic disorder (delusional, brief psychotic, paraphrenia, bipolar with psychotic features, major-depressive with psychotic features)
- access to protected internet (i.e., home internet plugged or password protected wireless)
- adequate space to do yoga (e.g., at least 2 feet around each side of the yoga mat)
- able to speak and read English
- competent and able to offer voluntary informed consent to participate
For non-clinical participants (healthy controls):
- not diagnosed with or received care for any mental illness
- access to protected internet (i.e., home internet plugged or password protected wireless)
- adequate space to do yoga (e.g., at least 2 feet around each side of the yoga mat)
- able to speak and read English
- competent and able to offer voluntary informed consent to participate
Exclusion Criteria:
For clinical participants:
- not clinically stable; that is, major change in primary medication (e.g., switching or stopping antipsychotic) or hospitalisation within the past 4 weeks prior to first contact
- currently with a physical ailment that restricts light movement exercises for yoga or chair yoga
For non-clinical participants (healthy controls):
- have a first-degree relative with psychosis (schizophrenia, schizo-affective, schizophreniform, paraphrenia, brief psychotic, delusional, or bipolar or major depressive disorder with psychotic features)
- had a substance or alcohol abuse/dependence in the past 6 months
- currently with a physical ailment that restricts light movement exercises for yoga or chair yoga
Sites / Locations
- The Royal Ottawa Mental Heatlh CentreRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Clinical
Non-clinical
Arm Description
Clinical participants with a primary diagnosis of psychosis or related disorder.
Non-clinical participants with no mental health diagnoses.
Outcomes
Primary Outcome Measures
Change from baseline on the Clinical Outcomes in Routine Evaluation (CORE-10) scale at week 4
The CORE-10 is a self-reported instrument measuring levels of psychological distress in the past week. Possible scores range from 0 (not at all) to 4 (most or all of the time). Higher score = worse outcome. Change = (week 4 - baseline).
Change from baseline on the Clinical Outcomes in Routine Evaluation (CORE-10) scale at week 8
The CORE-10 is a self-reported instrument measuring levels of psychological distress in the past week. Possible scores range from 0 (not at all) to 4 (most or all of the time). Higher score = worse outcome. Change = (week 8 - baseline).
Change from baseline on the Clinical Outcomes in Routine Evaluation (CORE-10) scale at week 12
The CORE-10 is a self-reported instrument measuring levels of psychological distress in the past week. Possible scores range from 0 (not at all) to 4 (most or all of the time). Higher score = worse outcome. Change = (week 12 - baseline).
Change from baseline on the Clinical Outcomes in Routine Evaluation (CORE-10) scale at 6 months
The CORE-10 is a self-reported instrument measuring levels of psychological distress in the past week. Possible scores range from 0 (not at all) to 4 (most or all of the time). Higher score = worse outcome. Change = (6 month - baseline).
Change from baseline on the Positive and Negative Syndrome Scale for Schizophrenia (PANSS) scale at 4 weeks
The PANSS is a clinician-rated, semi-structured interview assessing schizophrenia symptom severity over the past week. Possible scores range from 1 (absent) to 7 (extreme). Higher score = worse outcome. Change = (week 4 - baseline).
Change from baseline on the Positive and Negative Syndrome Scale for Schizophrenia (PANSS) scale at 8 weeks
The PANSS is a clinician-rated, semi-structured interview assessing schizophrenia symptom severity over the past week. Possible scores range from 1 (absent) to 7 (extreme). Higher score = worse outcome. Change = (week 8 - baseline).
Change from baseline on the Positive and Negative Syndrome Scale for Schizophrenia (PANSS) scale at 12 weeks
The PANSS is a clinician-rated, semi-structured interview assessing schizophrenia symptom severity over the past week. Possible scores range from 1 (absent) to 7 (extreme). Higher score = worse outcome. Change = (week 12 - baseline).
Change from baseline on the Positive and Negative Syndrome Scale for Schizophrenia (PANSS) scale at 6 months
The PANSS is a clinician-rated, semi-structured interview assessing schizophrenia symptom severity over the past week. Possible scores range from 1 (absent) to 7 (extreme). Higher score = worse outcome. Change = (6 month - baseline).
Change from baseline on the Questionnaire about the Process of Recovery - Version 2 (QPR-2) scale at week 4
The QPR-2 is a self-reported instrument assessing levels of recovery over the past week. Scores range from 0 (disagree strongly) to 4 (agree strongly). Higher score = better outcome. Change = (week 4 - baseline).
Change from baseline on the Questionnaire about the Process of Recovery - Version 2 (QPR-2) scale at week 8
The QPR-2 is a self-reported instrument assessing levels of recovery over the past week. Scores range from 0 (disagree strongly) to 4 (agree strongly). Higher score = better outcome. Change = (week 8 - baseline).
Change from baseline on the Questionnaire about the Process of Recovery - Version 2 (QPR-2) scale at week 12
The QPR-2 is a self-reported instrument assessing levels of recovery over the past week. Scores range from 0 (disagree strongly) to 4 (agree strongly). Higher score = better outcome. Change = (week 12 - baseline).
Change from baseline on the Questionnaire about the Process of Recovery - Version 2 (QPR-2) scale at 6 months
The QPR-2 is a self-reported instrument assessing levels of recovery over the past week. Scores range from 0 (disagree strongly) to 4 (agree strongly). Higher score = better outcome. Change = (6 months - baseline).
Change from baseline on the Self-Evaluation of Negative Symptoms (SNS) scale at week 4
The SNS is a self-reported instrument assessing negative symptom severity over the past week. Possible answers are strongly agree, somewhat agree, strongly disagree. Higher score = worse outcome. Change = (week 4 - baseline).
Change from baseline on the Self-Evaluation of Negative Symptoms (SNS) scale at week 8
The SNS is a self-reported instrument assessing negative symptom severity over the past week. Possible answers are strongly agree, somewhat agree, strongly disagree. Higher score = worse outcome. Change = (week 8 - baseline).
Change from baseline on the Self-Evaluation of Negative Symptoms (SNS) scale at week 12
The SNS is a self-reported instrument assessing negative symptom severity over the past week. Possible answers are strongly agree, somewhat agree, strongly disagree. Higher score = worse outcome. Change = (week 12 - baseline).
Change from baseline on the Self-Evaluation of Negative Symptoms (SNS) scale at 6 months
The SNS is a self-reported instrument assessing negative symptom severity over the past week. Possible answers are strongly agree, somewhat agree, strongly disagree. Higher score = worse outcome. Change = (6 months - baseline).
Change from baseline on the Birchwood Insight Scale (BIS) scale at week 4
The BIS is a self-reported instrument assessing levels of insight without a specific time period. Possible answers are agree, disagree, unsure. Higher score = better outcome. Change = (week 4 - baseline).
Change from baseline on the Birchwood Insight Scale (BIS) scale at week 8
The BIS is a self-reported instrument assessing levels of insight without a specific time period. Possible answers are agree, disagree, unsure. Higher score = better outcome. Change = (week 8 - baseline).
Change from baseline on the Birchwood Insight Scale (BIS) scale at week 12
The BIS is a self-reported instrument assessing levels of insight without a specific time period. Possible answers are agree, disagree, unsure. Higher score = better outcome. Change = (week 12 - baseline).
Change from baseline on the Birchwood Insight Scale (BIS) scale at 6 months
The BIS is a self-reported instrument assessing levels of insight without a specific time period. Possible answers are agree, disagree, unsure. Higher score = better outcome. Change = (6 months - baseline).
Change from baseline on the Short Warwick Edinburgh Mental Well-Being Scale (SWEMWBS) scale at week 4
The SWEMWBS is a self-reported instrument assessing levels of overall mental well-being over the past 2 weeks. Possible scores range from 1 (none of the time) to 5 (all of the time). Higher score = better outcome. Change = (week 4 - baseline).
Change from baseline on the Short Warwick Edinburgh Mental Well-Being Scale (SWEMWBS) scale at week 8
The SWEMWBS is a self-reported instrument assessing levels of overall mental well-being over the past 2 weeks. Possible scores range from 1 (none of the time) to 5 (all of the time). Higher score = better outcome. Change = (week 8 - baseline).
Change from baseline on the Short Warwick Edinburgh Mental Well-Being Scale (SWEMWBS) scale at week 12
The SWEMWBS is a self-reported instrument assessing levels of overall mental well-being over the past 2 weeks. Possible scores range from 1 (none of the time) to 5 (all of the time). Higher score = better outcome. Change = (week 12 - baseline).
Change from baseline on the Short Warwick Edinburgh Mental Well-Being Scale (SWEMWBS) scale at 6 months
The SWEMWBS is a self-reported instrument assessing levels of overall mental well-being over the past 2 weeks. Possible scores range from 1 (none of the time) to 5 (all of the time). Higher score = better outcome. Change = (6 months - baseline).
Change from baseline on the Modified Global Assessment of Functioning - Revised (M-GAF(R)) scale at week 4
The M-GAF(R) is a clinician-rated instrument assessing overall level of functioning over the past month. Score ranges from 1 (severely impaired) to 100 (superior functioning). Higher score = better outcome. Change = (week 4 - baseline).
Change from baseline on the Modified Global Assessment of Functioning - Revised (M-GAF(R)) scale at week 8
The M-GAF(R) is a clinician-rated instrument assessing overall level of functioning over the past month. Score ranges from 1 (severely impaired) to 100 (superior functioning). Higher score = better outcome. Change = (week 8 - baseline).
Change from baseline on the Modified Global Assessment of Functioning - Revised (M-GAF(R)) scale at week 12
The M-GAF(R) is a clinician-rated instrument assessing overall level of functioning over the past month. Score ranges from 1 (severely impaired) to 100 (superior functioning). Higher score = better outcome. Change = (week 12 - baseline).
Change from baseline on the Modified Global Assessment of Functioning - Revised (M-GAF(R)) scale at 6 months
The M-GAF(R) is a clinician-rated instrument assessing overall level of functioning over the past month. Score ranges from 1 (severely impaired) to 100 (superior functioning). Higher score = better outcome. Change = (6 months - baseline).
Secondary Outcome Measures
Full Information
NCT ID
NCT05046912
First Posted
June 15, 2021
Last Updated
June 13, 2022
Sponsor
The Royal Ottawa Mental Health Centre
1. Study Identification
Unique Protocol Identification Number
NCT05046912
Brief Title
Online Yoga and the Impact on Psychosis
Official Title
Exploring the Impact of Online Yoga on Outcome and Recovery in People With Psychosis.
Study Type
Interventional
2. Study Status
Record Verification Date
September 2021
Overall Recruitment Status
Unknown status
Study Start Date
November 11, 2021 (Actual)
Primary Completion Date
November 5, 2022 (Anticipated)
Study Completion Date
November 5, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The Royal Ottawa Mental Health Centre
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Yoga and mindfulness are considered complementary and alternative healthcare options that involve breathing techniques, relaxation, and bodily postures (yoga only). Research has shown a positive effect of these on depression, quality of life, and other symptoms of psychosis. As an 8-week pilot study, the goal is to offer yoga and/or mindfulness online and to explore the effect on recovery and quality of life for people with psychosis.
Detailed Description
Psychosis impacts about 3% of Canadians at any given time. People with psychosis can experience a combination of positive (e.g., delusions; hallucinations), negative (e.g., amotivation; reduced social activity), or cognitive symptoms (e.g., poorer memory; executive functioning). Positive symptoms are managed via antipsychotic medication and therapeutic support; cognitive symptoms can be targeted via cognitive remediation therapy. For negative symptoms, especially those idiopathic, there are still no effective care options. Yoga is a complementary and alternative medicine (CAM) encompassing health modalities of Eastern cultures, it involves breathing techniques, relaxation, and bodily postures. Research has shown that yoga can improve levels of depression and quality of life, and even attenuate negative symptoms. Given the extensive health care expenditures and unmet care needs for negative symptoms, there is a growing need to consider CAMs, such as yoga, and accessibility of CAMs via online methods. As a pioneering study, this proposed pilot study aims to explore the effect of an 8-week (i.e., 8 sessions) online yoga program on recovery/outcome, with a focus on negative symptoms, for people with psychosis. The investigators aim to recruit 24 people with psychosis and randomly assign them to either the yoga (n=12) or a mindfulness group (n=12); mindfulness, in essence, is yoga without the physical aspect (i.e., poses). The investigators hypothesize that yoga will improve quality of life and attenuate symptom severity, with a larger effect on negative symptoms, above the effect of mindfulness. A nonclinical sample (n=12) will also be recruited to examine feasibility and for feedback purposes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Psychosis
Keywords
Psychosis, Yoga, Mindfulness, Recovery, Online
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Clinical and non-clinical participants will be assigned to either a yoga or mindfulness condition.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
36 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Clinical
Arm Type
Experimental
Arm Description
Clinical participants with a primary diagnosis of psychosis or related disorder.
Arm Title
Non-clinical
Arm Type
Active Comparator
Arm Description
Non-clinical participants with no mental health diagnoses.
Intervention Type
Behavioral
Intervention Name(s)
Yoga
Intervention Description
8 weeks of online weekly yoga or chair yoga class
Intervention Type
Behavioral
Intervention Name(s)
Mindfulness
Intervention Description
8 weeks of online weekly mindfulness class
Primary Outcome Measure Information:
Title
Change from baseline on the Clinical Outcomes in Routine Evaluation (CORE-10) scale at week 4
Description
The CORE-10 is a self-reported instrument measuring levels of psychological distress in the past week. Possible scores range from 0 (not at all) to 4 (most or all of the time). Higher score = worse outcome. Change = (week 4 - baseline).
Time Frame
Baseline and Week 4
Title
Change from baseline on the Clinical Outcomes in Routine Evaluation (CORE-10) scale at week 8
Description
The CORE-10 is a self-reported instrument measuring levels of psychological distress in the past week. Possible scores range from 0 (not at all) to 4 (most or all of the time). Higher score = worse outcome. Change = (week 8 - baseline).
Time Frame
Baseline and Week 8
Title
Change from baseline on the Clinical Outcomes in Routine Evaluation (CORE-10) scale at week 12
Description
The CORE-10 is a self-reported instrument measuring levels of psychological distress in the past week. Possible scores range from 0 (not at all) to 4 (most or all of the time). Higher score = worse outcome. Change = (week 12 - baseline).
Time Frame
Baseline and Week 12
Title
Change from baseline on the Clinical Outcomes in Routine Evaluation (CORE-10) scale at 6 months
Description
The CORE-10 is a self-reported instrument measuring levels of psychological distress in the past week. Possible scores range from 0 (not at all) to 4 (most or all of the time). Higher score = worse outcome. Change = (6 month - baseline).
Time Frame
Baseline and 6 Months
Title
Change from baseline on the Positive and Negative Syndrome Scale for Schizophrenia (PANSS) scale at 4 weeks
Description
The PANSS is a clinician-rated, semi-structured interview assessing schizophrenia symptom severity over the past week. Possible scores range from 1 (absent) to 7 (extreme). Higher score = worse outcome. Change = (week 4 - baseline).
Time Frame
Baseline and Week 4
Title
Change from baseline on the Positive and Negative Syndrome Scale for Schizophrenia (PANSS) scale at 8 weeks
Description
The PANSS is a clinician-rated, semi-structured interview assessing schizophrenia symptom severity over the past week. Possible scores range from 1 (absent) to 7 (extreme). Higher score = worse outcome. Change = (week 8 - baseline).
Time Frame
Baseline and Week 8
Title
Change from baseline on the Positive and Negative Syndrome Scale for Schizophrenia (PANSS) scale at 12 weeks
Description
The PANSS is a clinician-rated, semi-structured interview assessing schizophrenia symptom severity over the past week. Possible scores range from 1 (absent) to 7 (extreme). Higher score = worse outcome. Change = (week 12 - baseline).
Time Frame
Baseline and Week 12
Title
Change from baseline on the Positive and Negative Syndrome Scale for Schizophrenia (PANSS) scale at 6 months
Description
The PANSS is a clinician-rated, semi-structured interview assessing schizophrenia symptom severity over the past week. Possible scores range from 1 (absent) to 7 (extreme). Higher score = worse outcome. Change = (6 month - baseline).
Time Frame
Baseline and 6 Months
Title
Change from baseline on the Questionnaire about the Process of Recovery - Version 2 (QPR-2) scale at week 4
Description
The QPR-2 is a self-reported instrument assessing levels of recovery over the past week. Scores range from 0 (disagree strongly) to 4 (agree strongly). Higher score = better outcome. Change = (week 4 - baseline).
Time Frame
Baseline and Week 4
Title
Change from baseline on the Questionnaire about the Process of Recovery - Version 2 (QPR-2) scale at week 8
Description
The QPR-2 is a self-reported instrument assessing levels of recovery over the past week. Scores range from 0 (disagree strongly) to 4 (agree strongly). Higher score = better outcome. Change = (week 8 - baseline).
Time Frame
Baseline and Week 8
Title
Change from baseline on the Questionnaire about the Process of Recovery - Version 2 (QPR-2) scale at week 12
Description
The QPR-2 is a self-reported instrument assessing levels of recovery over the past week. Scores range from 0 (disagree strongly) to 4 (agree strongly). Higher score = better outcome. Change = (week 12 - baseline).
Time Frame
Baseline and Week 12
Title
Change from baseline on the Questionnaire about the Process of Recovery - Version 2 (QPR-2) scale at 6 months
Description
The QPR-2 is a self-reported instrument assessing levels of recovery over the past week. Scores range from 0 (disagree strongly) to 4 (agree strongly). Higher score = better outcome. Change = (6 months - baseline).
Time Frame
Baseline and 6 Months
Title
Change from baseline on the Self-Evaluation of Negative Symptoms (SNS) scale at week 4
Description
The SNS is a self-reported instrument assessing negative symptom severity over the past week. Possible answers are strongly agree, somewhat agree, strongly disagree. Higher score = worse outcome. Change = (week 4 - baseline).
Time Frame
Baseline and Week 4
Title
Change from baseline on the Self-Evaluation of Negative Symptoms (SNS) scale at week 8
Description
The SNS is a self-reported instrument assessing negative symptom severity over the past week. Possible answers are strongly agree, somewhat agree, strongly disagree. Higher score = worse outcome. Change = (week 8 - baseline).
Time Frame
Baseline and Week 8
Title
Change from baseline on the Self-Evaluation of Negative Symptoms (SNS) scale at week 12
Description
The SNS is a self-reported instrument assessing negative symptom severity over the past week. Possible answers are strongly agree, somewhat agree, strongly disagree. Higher score = worse outcome. Change = (week 12 - baseline).
Time Frame
Baseline and Week 12
Title
Change from baseline on the Self-Evaluation of Negative Symptoms (SNS) scale at 6 months
Description
The SNS is a self-reported instrument assessing negative symptom severity over the past week. Possible answers are strongly agree, somewhat agree, strongly disagree. Higher score = worse outcome. Change = (6 months - baseline).
Time Frame
Baseline and 6 Months
Title
Change from baseline on the Birchwood Insight Scale (BIS) scale at week 4
Description
The BIS is a self-reported instrument assessing levels of insight without a specific time period. Possible answers are agree, disagree, unsure. Higher score = better outcome. Change = (week 4 - baseline).
Time Frame
Baseline and Week 4
Title
Change from baseline on the Birchwood Insight Scale (BIS) scale at week 8
Description
The BIS is a self-reported instrument assessing levels of insight without a specific time period. Possible answers are agree, disagree, unsure. Higher score = better outcome. Change = (week 8 - baseline).
Time Frame
Baseline and Week 8
Title
Change from baseline on the Birchwood Insight Scale (BIS) scale at week 12
Description
The BIS is a self-reported instrument assessing levels of insight without a specific time period. Possible answers are agree, disagree, unsure. Higher score = better outcome. Change = (week 12 - baseline).
Time Frame
Baseline and Week 12
Title
Change from baseline on the Birchwood Insight Scale (BIS) scale at 6 months
Description
The BIS is a self-reported instrument assessing levels of insight without a specific time period. Possible answers are agree, disagree, unsure. Higher score = better outcome. Change = (6 months - baseline).
Time Frame
Baseline and 6 Months
Title
Change from baseline on the Short Warwick Edinburgh Mental Well-Being Scale (SWEMWBS) scale at week 4
Description
The SWEMWBS is a self-reported instrument assessing levels of overall mental well-being over the past 2 weeks. Possible scores range from 1 (none of the time) to 5 (all of the time). Higher score = better outcome. Change = (week 4 - baseline).
Time Frame
Baseline and Week 4
Title
Change from baseline on the Short Warwick Edinburgh Mental Well-Being Scale (SWEMWBS) scale at week 8
Description
The SWEMWBS is a self-reported instrument assessing levels of overall mental well-being over the past 2 weeks. Possible scores range from 1 (none of the time) to 5 (all of the time). Higher score = better outcome. Change = (week 8 - baseline).
Time Frame
Baseline and Week 8
Title
Change from baseline on the Short Warwick Edinburgh Mental Well-Being Scale (SWEMWBS) scale at week 12
Description
The SWEMWBS is a self-reported instrument assessing levels of overall mental well-being over the past 2 weeks. Possible scores range from 1 (none of the time) to 5 (all of the time). Higher score = better outcome. Change = (week 12 - baseline).
Time Frame
Baseline and Week 12
Title
Change from baseline on the Short Warwick Edinburgh Mental Well-Being Scale (SWEMWBS) scale at 6 months
Description
The SWEMWBS is a self-reported instrument assessing levels of overall mental well-being over the past 2 weeks. Possible scores range from 1 (none of the time) to 5 (all of the time). Higher score = better outcome. Change = (6 months - baseline).
Time Frame
Baseline and 6 Months
Title
Change from baseline on the Modified Global Assessment of Functioning - Revised (M-GAF(R)) scale at week 4
Description
The M-GAF(R) is a clinician-rated instrument assessing overall level of functioning over the past month. Score ranges from 1 (severely impaired) to 100 (superior functioning). Higher score = better outcome. Change = (week 4 - baseline).
Time Frame
Baseline and Week 4
Title
Change from baseline on the Modified Global Assessment of Functioning - Revised (M-GAF(R)) scale at week 8
Description
The M-GAF(R) is a clinician-rated instrument assessing overall level of functioning over the past month. Score ranges from 1 (severely impaired) to 100 (superior functioning). Higher score = better outcome. Change = (week 8 - baseline).
Time Frame
Baseline and Week 8
Title
Change from baseline on the Modified Global Assessment of Functioning - Revised (M-GAF(R)) scale at week 12
Description
The M-GAF(R) is a clinician-rated instrument assessing overall level of functioning over the past month. Score ranges from 1 (severely impaired) to 100 (superior functioning). Higher score = better outcome. Change = (week 12 - baseline).
Time Frame
Baseline and Week 12
Title
Change from baseline on the Modified Global Assessment of Functioning - Revised (M-GAF(R)) scale at 6 months
Description
The M-GAF(R) is a clinician-rated instrument assessing overall level of functioning over the past month. Score ranges from 1 (severely impaired) to 100 (superior functioning). Higher score = better outcome. Change = (6 months - baseline).
Time Frame
Baseline and 6 Months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
For clinical participants:
primary diagnosis of a schizophrenia-spectrum disorder (schizophrenia, schizophreniform, schizoaffective) or related psychotic disorder (delusional, brief psychotic, paraphrenia, bipolar with psychotic features, major-depressive with psychotic features)
access to protected internet (i.e., home internet plugged or password protected wireless)
adequate space to do yoga (e.g., at least 2 feet around each side of the yoga mat)
able to speak and read English
competent and able to offer voluntary informed consent to participate
For non-clinical participants (healthy controls):
not diagnosed with or received care for any mental illness
access to protected internet (i.e., home internet plugged or password protected wireless)
adequate space to do yoga (e.g., at least 2 feet around each side of the yoga mat)
able to speak and read English
competent and able to offer voluntary informed consent to participate
Exclusion Criteria:
For clinical participants:
not clinically stable; that is, major change in primary medication (e.g., switching or stopping antipsychotic) or hospitalisation within the past 4 weeks prior to first contact
currently with a physical ailment that restricts light movement exercises for yoga or chair yoga
For non-clinical participants (healthy controls):
have a first-degree relative with psychosis (schizophrenia, schizo-affective, schizophreniform, paraphrenia, brief psychotic, delusional, or bipolar or major depressive disorder with psychotic features)
had a substance or alcohol abuse/dependence in the past 6 months
currently with a physical ailment that restricts light movement exercises for yoga or chair yoga
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Michael Bodnar, PhD
Phone
(613) 722-6521
Ext
6711
Email
michael.bodnar@theroyal.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Bodnar, PhD
Organizational Affiliation
The Royal Ottawa Mental Health Centre
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Royal Ottawa Mental Heatlh Centre
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1Z7K4
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Bodnar, PhD
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
26652054
Citation
Andersson G. Internet-Delivered Psychological Treatments. Annu Rev Clin Psychol. 2016;12:157-79. doi: 10.1146/annurev-clinpsy-021815-093006. Epub 2015 Dec 11.
Results Reference
background
PubMed Identifier
30600624
Citation
Andersson G, Titov N, Dear BF, Rozental A, Carlbring P. Internet-delivered psychological treatments: from innovation to implementation. World Psychiatry. 2019 Feb;18(1):20-28. doi: 10.1002/wps.20610.
Results Reference
background
PubMed Identifier
27928859
Citation
Aust J, Bradshaw T. Mindfulness interventions for psychosis: a systematic review of the literature. J Psychiatr Ment Health Nurs. 2017 Feb;24(1):69-83. doi: 10.1111/jpm.12357. Epub 2016 Dec 8.
Results Reference
background
PubMed Identifier
14609805
Citation
Bartels SJ, Clark RE, Peacock WJ, Dums AR, Pratt SI. Medicare and medicaid costs for schizophrenia patients by age cohort compared with costs for depression, dementia, and medically ill patients. Am J Geriatr Psychiatry. 2003 Nov-Dec;11(6):648-57. doi: 10.1176/appi.ajgp.11.6.648.
Results Reference
background
PubMed Identifier
24049210
Citation
Jayaram N, Varambally S, Behere RV, Venkatasubramanian G, Arasappa R, Christopher R, Gangadhar BN. Effect of yoga therapy on plasma oxytocin and facial emotion recognition deficits in patients of schizophrenia. Indian J Psychiatry. 2013 Jul;55(Suppl 3):S409-13. doi: 10.4103/0019-5545.116318.
Results Reference
background
PubMed Identifier
7908156
Citation
Birchwood M, Smith J, Drury V, Healy J, Macmillan F, Slade M. A self-report Insight Scale for psychosis: reliability, validity and sensitivity to change. Acta Psychiatr Scand. 1994 Jan;89(1):62-7. doi: 10.1111/j.1600-0447.1994.tb01487.x.
Results Reference
background
PubMed Identifier
21611123
Citation
Chang CK, Hayes RD, Perera G, Broadbent MT, Fernandes AC, Lee WE, Hotopf M, Stewart R. Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London. PLoS One. 2011;6(5):e19590. doi: 10.1371/journal.pone.0019590. Epub 2011 May 18.
Results Reference
background
PubMed Identifier
26937312
Citation
Cramer H, Lauche R, Haller H, Langhorst J, Dobos G. Mindfulness- and Acceptance-based Interventions for Psychosis: A Systematic Review and Meta-analysis. Glob Adv Health Med. 2016 Jan;5(1):30-43. doi: 10.7453/gahmj.2015.083. Epub 2016 Jan 1.
Results Reference
background
PubMed Identifier
26564898
Citation
Dollfus S, Mach C, Morello R. Self-Evaluation of Negative Symptoms: A Novel Tool to Assess Negative Symptoms. Schizophr Bull. 2016 May;42(3):571-8. doi: 10.1093/schbul/sbv161. Epub 2015 Nov 12.
Results Reference
background
PubMed Identifier
17655565
Citation
Duraiswamy G, Thirthalli J, Nagendra HR, Gangadhar BN. Yoga therapy as an add-on treatment in the management of patients with schizophrenia--a randomized controlled trial. Acta Psychiatr Scand. 2007 Sep;116(3):226-32. doi: 10.1111/j.1600-0447.2007.01032.x.
Results Reference
background
PubMed Identifier
24275699
Citation
Foussias G, Agid O, Fervaha G, Remington G. Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders. Eur Neuropsychopharmacol. 2014 May;24(5):693-709. doi: 10.1016/j.euroneuro.2013.10.017. Epub 2013 Nov 11.
Results Reference
background
PubMed Identifier
3616518
Citation
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76. doi: 10.1093/schbul/13.2.261.
Results Reference
background
PubMed Identifier
30037286
Citation
Kolbaek P, Blicher AB, Buus CW, Feller SG, Holm T, Dines D, O'Leary KM, Sorensen RS, Opler M, Correll CU, Mors O, Bech P, Ostergaard SD. Inter-rater reliability of ratings on the six-item Positive and Negative Syndrome Scale (PANSS-6) obtained using the Simplified Negative and Positive Symptoms Interview (SNAPSI). Nord J Psychiatry. 2018 Aug;72(6):431-436. doi: 10.1080/08039488.2018.1492014. Epub 2018 Jul 24.
Results Reference
background
PubMed Identifier
29368205
Citation
Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Nikolakopoulou A, Leucht S. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2018 Oct;268(7):625-639. doi: 10.1007/s00406-018-0869-3. Epub 2018 Jan 24.
Results Reference
background
PubMed Identifier
24581453
Citation
Leucht S. Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application. J Clin Psychiatry. 2014;75 Suppl 1:8-14. doi: 10.4088/JCP.13049su1c.02.
Results Reference
background
PubMed Identifier
28541090
Citation
Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, Samara M, Rabaioli M, Bacher S, Cipriani A, Geddes JR, Salanti G, Davis JM. Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors. Am J Psychiatry. 2017 Oct 1;174(10):927-942. doi: 10.1176/appi.ajp.2017.16121358. Epub 2017 May 25.
Results Reference
background
PubMed Identifier
26558537
Citation
Ostergaard SD, Lemming OM, Mors O, Correll CU, Bech P. PANSS-6: a brief rating scale for the measurement of severity in schizophrenia. Acta Psychiatr Scand. 2016 Jun;133(6):436-44. doi: 10.1111/acps.12526. Epub 2015 Nov 12.
Results Reference
background
PubMed Identifier
29410939
Citation
Ostergaard SD, Opler MGA, Correll CU. Bridging the Measurement Gap Between Research and Clinical Care in Schizophrenia: Positive and Negative Syndrome Scale-6 (PANSS-6) and Other Assessments Based on the Simplified Negative and Positive Symptoms Interview (SNAPSI). Innov Clin Neurosci. 2017 Dec 1;14(11-12):68-72.
Results Reference
background
PubMed Identifier
9881538
Citation
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57.
Results Reference
background
PubMed Identifier
27111302
Citation
Spijkerman MP, Pots WT, Bohlmeijer ET. Effectiveness of online mindfulness-based interventions in improving mental health: A review and meta-analysis of randomised controlled trials. Clin Psychol Rev. 2016 Apr;45:102-14. doi: 10.1016/j.cpr.2016.03.009. Epub 2016 Apr 1.
Results Reference
background
PubMed Identifier
18042300
Citation
Tennant R, Hiller L, Fishwick R, Platt S, Joseph S, Weich S, Parkinson J, Secker J, Stewart-Brown S. The Warwick-Edinburgh Mental Well-being Scale (WEMWBS): development and UK validation. Health Qual Life Outcomes. 2007 Nov 27;5:63. doi: 10.1186/1477-7525-5-63.
Results Reference
background
PubMed Identifier
29320386
Citation
Uebelacker L, Dufour SC, Dinerman JG, Walsh SL, Hearing C, Gillette LT, Deckersbach T, Nierenberg AA, Weinstock L, Sylvia LG. Examining the Feasibility and Acceptability of an Online Yoga Class for Mood Disorders: A MoodNetwork Study. J Psychiatr Pract. 2018 Jan;24(1):60-67. doi: 10.1097/PRA.0000000000000286.
Results Reference
background
PubMed Identifier
24129842
Citation
van der Krieke L, Wunderink L, Emerencia AC, de Jonge P, Sytema S. E-mental health self-management for psychotic disorders: state of the art and future perspectives. Psychiatr Serv. 2014 Jan 1;65(1):33-49. doi: 10.1176/appi.ps.201300050.
Results Reference
background
PubMed Identifier
22486714
Citation
Vancampfort D, Vansteelandt K, Scheewe T, Probst M, Knapen J, De Herdt A, De Hert M. Yoga in schizophrenia: a systematic review of randomised controlled trials. Acta Psychiatr Scand. 2012 Jul;126(1):12-20. doi: 10.1111/j.1600-0447.2012.01865.x. Epub 2012 Apr 6.
Results Reference
background
PubMed Identifier
22813667
Citation
Varambally S, Gangadhar BN. Yoga: a spiritual practice with therapeutic value in psychiatry. Asian J Psychiatr. 2012 Jun;5(2):186-9. doi: 10.1016/j.ajp.2012.05.003. Epub 2012 May 18.
Results Reference
background
PubMed Identifier
23226845
Citation
Varambally S, Gangadhar BN, Thirthalli J, Jagannathan A, Kumar S, Venkatasubramanian G, Muralidhar D, Subbakrishna DK, Nagendra HR. Therapeutic efficacy of add-on yogasana intervention in stabilized outpatient schizophrenia: Randomized controlled comparison with exercise and waitlist. Indian J Psychiatry. 2012 Jul;54(3):227-32. doi: 10.4103/0019-5545.102414.
Results Reference
background
PubMed Identifier
21711202
Citation
Visceglia E, Lewis S. Yoga therapy as an adjunctive treatment for schizophrenia: a randomized, controlled pilot study. J Altern Complement Med. 2011 Jul;17(7):601-7. doi: 10.1089/acm.2010.0075.
Results Reference
background
PubMed Identifier
22352291
Citation
Wolever RQ, Bobinet KJ, McCabe K, Mackenzie ER, Fekete E, Kusnick CA, Baime M. Effective and viable mind-body stress reduction in the workplace: a randomized controlled trial. J Occup Health Psychol. 2012 Apr;17(2):246-258. doi: 10.1037/a0027278. Epub 2012 Feb 20.
Results Reference
background
Learn more about this trial
Online Yoga and the Impact on Psychosis
We'll reach out to this number within 24 hrs